GE HealthCare Q2 Orders Surge 11%, PCS Segment Under Strategic Review
GEHC sits 17% above its 52-week low of $58.75.
Summary
GE HealthCare posted a strong Q2 with orders up 11%, well above mid-single-digit expectations, driving revenue to $5.3B and adjusted EPS of $1.13, beating consensus. The company also disclosed a strategic review of its struggling Patient Care Solutions segment, which saw revenue drop 13%, signaling a potential divestiture. Q3 guidance calls for 3-4% organic revenue growth and low-double-digit adjusted EPS growth, with full-year outlook reaffirmed. Shares surged 12% to $71.90 on the news. This follows the CFO departure announced last week and the preliminary results on July 23, adding clarity on segment performance and capital allocation priorities.
At the time of this announcement, GEHC was trading at $68.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.3B. The 52-week trading range was $58.75 to $89.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.